Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Operating Leases: 2023-2025

Historic Operating Leases for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $8.5 million.

  • Artiva Biotherapeutics' Operating Leases fell 23.66% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 23.66%. This contributed to the annual value of $10.6 million for FY2024, which is 20.62% down from last year.
  • Per Artiva Biotherapeutics' latest filing, its Operating Leases stood at $8.5 million for Q3 2025, which was down 11.09% from $9.6 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Operating Leases high stood at $15.5 million for Q2 2024, and its period low was $8.5 million during Q3 2025.
  • In the last 3 years, Artiva Biotherapeutics' Operating Leases had a median value of $10.6 million in 2024 and averaged $11.3 million.
  • Data for Artiva Biotherapeutics' Operating Leases shows a maximum YoY tumbled of 38.35% (in 2025) over the last 5 years.
  • Artiva Biotherapeutics' Operating Leases (Quarterly) stood at $13.3 million in 2023, then decreased by 20.62% to $10.6 million in 2024, then dropped by 23.66% to $8.5 million in 2025.
  • Its Operating Leases was $8.5 million in Q3 2025, compared to $9.6 million in Q2 2025 and $10.3 million in Q1 2025.